In Vitro Antitumor Structure–Activity Relationships of threo/trans/threo mono-Tetrahydrofuranic Acetogenins: Correlations With Their Inhibition of Mitochondrial Complex I
In this study we evaluated a mono-tetrahydrofuranic subgroup of natural acetogenins that had shown in previous enzyme inhibition studies different potency trends compared with the bis-tetrahydrofuranic acetogenin subgroup. The compounds were tested against colon, breast, lung, liver, and ovarian tumor cell lines. A drug-resistant ovarian cell line was also included in the panel. In general the compounds were more potent than doxorubicin. The goal was to determine how well the mitochondrial complex I inhibition correlates with the in vitro antitumor potency of these natural mono-tetrahydrofuranic acetogenins and of some derivatives. The results indicate that both the reduction of the terminal γ-lactone after its translactonization and the introduction of an hydroxylimine group in the alkyl chain, near the mono-tetrahydrofuranic moiety, increased the antitumor activity, even against the doxorubicin-resistant cell line.
No Supplementary Data
No Article Media
Mitochondrial respiratory chain inhibitors;
Tumor cell line growth inhibitors
Document Type: Research Article
*CIBE-Merck Research Laboratories, Merck, Sharp & Dohme de España S.A., C/ Josefa Valcárcel, 38, Madrid 28027, Spain
†Departament de Farmacologia Facultat de Farmàcia, Universitat de València, Avgd. Vicent Andrés Estellés s/n, Burjassot 46100, València, Spain
Publication date: January 1, 2003
More about this publication?
Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.